Guotai Haitong: Maintains "buy" rating on GENSCRIPT BIO(01548), driving growth through innovation.

Guotai Haitong released a research report stating that it maintains a "buy" rating on GENSCRIPT BIO (01548) with a target price of HK$26.21 per share. The company's core development strategy is centered around "technology-driven" and "globalization layout," with a clear long-term revenue growth target and growth path for each sector. The company is optimistic about the long-term development trend of the company. Key points from Guotai Haitong: - Long-term strategic blueprint to create a globally leading biopharmaceutical ecosystem. - Focus on high-quality growth to enhance profitability, targeting to achieve over $3 billion in revenue by 2035 with an operating profit margin of over 20%. - Ensure stable growth of the basic business. - Strengthen growth-oriented businesses for certain growth and seek industry breakout opportunities. - Profit forecasts and ratings. Risk factors include a decline in the global biopharmaceutical R&D sentiment, unexpected progress in external authorization pipelines, intensified industry competition, and global macro-geopolitical risks.